Cognitive impairment in degenerative parkinsonisms: Role of radionuclide brain imaging

D. Arnaldi, S. Morbelli, E. Morrone, C. Campus, Flavio Nobili

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cognitive impairment in Parkinson's disease (PD) and atypical parkinsonian syndromes is gaining increased clinical significance. The neurochemical and neuropathological basis in the various parkinsonian forms and even in an individual patient are not fully elucidated yet and could be heterogeneous. Loss of dopaminergic, cholinergic and noradrenergic innervation has been suggested to be the underlying neurochemical deficits for cognitive impairment and dementia in PD, but the onset of cognitive impairment and the progression to dementia may not share the same underlying neurochemical basis. Similarly, pathological evidence is also heterogeneous, ranging from subcortical pathology, limbic or cortical Lewy body type degeneration, and Alzheimer's type pathology that can be found even in the same patient with PD dementia (PDD). Typically, the prototype of early cognitive deficit in PD is a dysexecutive syndrome, but other cognitive domains are more involved when dementia develops, mainly including visuospatial, language and memory dysfunction. Functional radionuclide neuroimaging, by means of single-photon emission computed tomography and positron emission tomography, are contributing to characterize the topographic cortical pattern of cognitive impairment, as well as to define the underlying neurochemical deficit. Lastly, the advent of amyloid PET may help clarifying the meaning of amyloid load in diffuse Lewy body disease and PDD. Knowing the neurochemical and pathophysiological substrate of cognitive deficit in patients with PD or other degenerative Parkinsonisms may help the clinician in understanding the clinical condition of an individual patient in order to plan pharmacological and non-pharmacological intervention. The introduction of acetylcholinesterase inhibitors for therapy of PDD is an example of information integration between clinical-neuropsychological and pathophysiological- neurochemical aspects obtained also with the key contribution of functional neuroimaging.

Original languageEnglish
Pages (from-to)55-67
Number of pages13
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume56
Issue number1
Publication statusPublished - Feb 2012

Fingerprint

Neuroimaging
Radionuclide Imaging
Dementia
Parkinson Disease
Functional Neuroimaging
Amyloid
Pathology
Lewy Bodies
Lewy Body Disease
Somatotypes
Cholinesterase Inhibitors
Parkinsonian Disorders
Single-Photon Emission-Computed Tomography
Radioisotopes
Positron-Emission Tomography
Cholinergic Agents
Cognitive Dysfunction
Language
Pharmacology

Keywords

  • Parkinson disease
  • Positron-emission tomography
  • Tomography, emission-computed, single-photon

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Cognitive impairment in degenerative parkinsonisms : Role of radionuclide brain imaging. / Arnaldi, D.; Morbelli, S.; Morrone, E.; Campus, C.; Nobili, Flavio.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 56, No. 1, 02.2012, p. 55-67.

Research output: Contribution to journalArticle

@article{8bf07d8cdbdf4665a2dff8143f0f275b,
title = "Cognitive impairment in degenerative parkinsonisms: Role of radionuclide brain imaging",
abstract = "Cognitive impairment in Parkinson's disease (PD) and atypical parkinsonian syndromes is gaining increased clinical significance. The neurochemical and neuropathological basis in the various parkinsonian forms and even in an individual patient are not fully elucidated yet and could be heterogeneous. Loss of dopaminergic, cholinergic and noradrenergic innervation has been suggested to be the underlying neurochemical deficits for cognitive impairment and dementia in PD, but the onset of cognitive impairment and the progression to dementia may not share the same underlying neurochemical basis. Similarly, pathological evidence is also heterogeneous, ranging from subcortical pathology, limbic or cortical Lewy body type degeneration, and Alzheimer's type pathology that can be found even in the same patient with PD dementia (PDD). Typically, the prototype of early cognitive deficit in PD is a dysexecutive syndrome, but other cognitive domains are more involved when dementia develops, mainly including visuospatial, language and memory dysfunction. Functional radionuclide neuroimaging, by means of single-photon emission computed tomography and positron emission tomography, are contributing to characterize the topographic cortical pattern of cognitive impairment, as well as to define the underlying neurochemical deficit. Lastly, the advent of amyloid PET may help clarifying the meaning of amyloid load in diffuse Lewy body disease and PDD. Knowing the neurochemical and pathophysiological substrate of cognitive deficit in patients with PD or other degenerative Parkinsonisms may help the clinician in understanding the clinical condition of an individual patient in order to plan pharmacological and non-pharmacological intervention. The introduction of acetylcholinesterase inhibitors for therapy of PDD is an example of information integration between clinical-neuropsychological and pathophysiological- neurochemical aspects obtained also with the key contribution of functional neuroimaging.",
keywords = "Parkinson disease, Positron-emission tomography, Tomography, emission-computed, single-photon",
author = "D. Arnaldi and S. Morbelli and E. Morrone and C. Campus and Flavio Nobili",
year = "2012",
month = "2",
language = "English",
volume = "56",
pages = "55--67",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Cognitive impairment in degenerative parkinsonisms

T2 - Role of radionuclide brain imaging

AU - Arnaldi, D.

AU - Morbelli, S.

AU - Morrone, E.

AU - Campus, C.

AU - Nobili, Flavio

PY - 2012/2

Y1 - 2012/2

N2 - Cognitive impairment in Parkinson's disease (PD) and atypical parkinsonian syndromes is gaining increased clinical significance. The neurochemical and neuropathological basis in the various parkinsonian forms and even in an individual patient are not fully elucidated yet and could be heterogeneous. Loss of dopaminergic, cholinergic and noradrenergic innervation has been suggested to be the underlying neurochemical deficits for cognitive impairment and dementia in PD, but the onset of cognitive impairment and the progression to dementia may not share the same underlying neurochemical basis. Similarly, pathological evidence is also heterogeneous, ranging from subcortical pathology, limbic or cortical Lewy body type degeneration, and Alzheimer's type pathology that can be found even in the same patient with PD dementia (PDD). Typically, the prototype of early cognitive deficit in PD is a dysexecutive syndrome, but other cognitive domains are more involved when dementia develops, mainly including visuospatial, language and memory dysfunction. Functional radionuclide neuroimaging, by means of single-photon emission computed tomography and positron emission tomography, are contributing to characterize the topographic cortical pattern of cognitive impairment, as well as to define the underlying neurochemical deficit. Lastly, the advent of amyloid PET may help clarifying the meaning of amyloid load in diffuse Lewy body disease and PDD. Knowing the neurochemical and pathophysiological substrate of cognitive deficit in patients with PD or other degenerative Parkinsonisms may help the clinician in understanding the clinical condition of an individual patient in order to plan pharmacological and non-pharmacological intervention. The introduction of acetylcholinesterase inhibitors for therapy of PDD is an example of information integration between clinical-neuropsychological and pathophysiological- neurochemical aspects obtained also with the key contribution of functional neuroimaging.

AB - Cognitive impairment in Parkinson's disease (PD) and atypical parkinsonian syndromes is gaining increased clinical significance. The neurochemical and neuropathological basis in the various parkinsonian forms and even in an individual patient are not fully elucidated yet and could be heterogeneous. Loss of dopaminergic, cholinergic and noradrenergic innervation has been suggested to be the underlying neurochemical deficits for cognitive impairment and dementia in PD, but the onset of cognitive impairment and the progression to dementia may not share the same underlying neurochemical basis. Similarly, pathological evidence is also heterogeneous, ranging from subcortical pathology, limbic or cortical Lewy body type degeneration, and Alzheimer's type pathology that can be found even in the same patient with PD dementia (PDD). Typically, the prototype of early cognitive deficit in PD is a dysexecutive syndrome, but other cognitive domains are more involved when dementia develops, mainly including visuospatial, language and memory dysfunction. Functional radionuclide neuroimaging, by means of single-photon emission computed tomography and positron emission tomography, are contributing to characterize the topographic cortical pattern of cognitive impairment, as well as to define the underlying neurochemical deficit. Lastly, the advent of amyloid PET may help clarifying the meaning of amyloid load in diffuse Lewy body disease and PDD. Knowing the neurochemical and pathophysiological substrate of cognitive deficit in patients with PD or other degenerative Parkinsonisms may help the clinician in understanding the clinical condition of an individual patient in order to plan pharmacological and non-pharmacological intervention. The introduction of acetylcholinesterase inhibitors for therapy of PDD is an example of information integration between clinical-neuropsychological and pathophysiological- neurochemical aspects obtained also with the key contribution of functional neuroimaging.

KW - Parkinson disease

KW - Positron-emission tomography

KW - Tomography, emission-computed, single-photon

UR - http://www.scopus.com/inward/record.url?scp=84861324426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861324426&partnerID=8YFLogxK

M3 - Article

C2 - 22460160

AN - SCOPUS:84861324426

VL - 56

SP - 55

EP - 67

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 1

ER -